Access Menu

Log in via Social

Log in with LinkedIn
ImmunoScience, Inc.

ImmunoScience, Inc.

Novel therapies leading to a functional cure for multiple cancers and HIV.

Company Overview

For our longer, more detailed video presentation visit:

http://immunoscience.com/en/video.html

ImmunoScience, Inc. is a biotechnology company specializing in the therapeutic treatment of immunologic disorders such as cancer and HIV. Located in Dublin, California, ImmunoScience combines innovation and ingenuity to develop cures for morbid diseases heretofore incurable. The company was founded in 1995 by Dr. Sateesh Apté, a board qualified physician who trained at Harvard Medical School and Stanford University Medical Center.

ImmunoScience has begun development of its most significant product, an as yet unnamed therapeutic vaccine for various types of cancer. ImmunoScience is negotiating a collaboration agreement with scientists at L’Institut Curie (The Curie Institute), a prestigious cancer research institute which is affiliated with the Pasteur Institute. The company believes this vaccine has the potential to be a universal therapy for cancer

ImmunoScience's original product is Contre Vir™, a therapeutic vaccine that utilizes a recombinant, live, attenuated virus for the treatment and potential cure of AIDS and the HIV infection. Invented by Dr. Apté, Contre Vir™ has shown a significantly high level of success in pre-clinical studies and pilot trials. The company expects success with efficacy data after completion of Phase I Clinical Trials which are expected to start in 2019.

ImmunoScience has several patents for Contre Vir™in the United States and internationally and anticipates the cancer vaccine will result in several dozen patents as well. Contre Vir™ is expected to start Phase I clinical trials in the very near future. The preliminary work for these trials will be undertaken in the United States, Belgium, United Kingdom and Africa.

ImmunoScience considers its technologies to be ground-breaking steps forward in the fight against cancer and HIV.

The Company has also developed a line of saliva-based rapid diagnostic products, the first of which is Salivax™-HIV, and also includes tests for Hepatitis B & C.These diagnostic kits are ready for market entry. ImmunoScience’s Indian subsidiary makes rapid test kits for diagnosis of malaria, dengue fever and chikungunya, which are designed for the Indian sub-continent as well as Asia and Africa where those diseases are prevalent.Sales have begun and will increase regularly.

CANCER VACCINE

Cancer is the generic term for the group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. According to the WHO, approximate 8.2 million people die every year from cancer with about 14 million new cases every year. The WHO projects that in the next two decades, without a means to stop it, the number of new cancer cases will continue to increase significantly.Our scientific team has believed for quite some time that cancer is, at its primary level, an immunologic disease brought on by assaults by external entities such as chemicals or excess UV radiation to create or trigger formation of aberrant cells which evade the immune system. This is now widely accepted by the cancer research community. In the simplest explanation, cancer consists of aberrant cells that are able to disguise themselves from the body's immune system and grow unchecked.The human body produces potential cancer cells all the time and a well-functioning immune system does not allow them to grow, killing them as they are identified.It is now recognized that immunologic treatment of cancer should be possible, and this is borne out by the fact that several immunologic treatments for some types of cancer have been very successful. For example, former President Jimmy Carter was cured of his metastasized melanoma by use of pembrolizumab, an antibody designed to attack the cancer. There are several examples of similar immunotherapy antibodies effective against a few other cancers.

Instead of using a single cancer antibody treatment for one cancer, ImmunoScience is working on a live virus (a “vector”) that will contain a "payload" delivery of different cancer markers simultaneously. This payload will also include constructs to suppress the mechanisms that cancer cells use to evade the immune system. By using a vector that will persistently activate the immune system, ImmunoScience expects that its proposed cancer vaccine will become the premier treatment modality for many, if not all, cancers.The advantages of such treatment will be significant.Chemotherapy and radiation treatment, and their adverse side-effects could be eliminated.Vaccine treatments should require relatively few injections.Depending on the progress of the cancer when detected, surgery may not be required.The cure and survival rates for cancer will be greatly increased, and treatment costs will be hugely decreased.Our vaccine will not need to be “customized” for each patient unlike many treatments that use autologous cells from each patient in order to modify them to fight cancer..

As opposed to HIV research, there are significant advantages inherent in our cancer research in that we can validate proof of concept in animal studies, something that cannot be done with respect to HIV.

THE HIV THERAPEUTIC VACCINE

Contre Vir™ is a therapeutic HIV vaccine, thus it is designed to be given to patients currently infected with the HIV virus. Contre Vir™ utilizes a recombinant live HIV-1 virus weakened by a deletion of the nef gene of HIV. The nef gene has been shown to be primarily responsible for the ability of the HIV to successfully evade the body's immune response. The deletion of the nef gene enables infected cells to present vaccine HIV antigens in conjunction with surface proteins, thus activating CD8 cytotoxic T lymphocytes to kill and clear the virus. Contre Vir™ allows the body to reestablish and reinvigorate the immune response system in order to stop the disease before it becomes fatal. The virus is rendered non- pathogenic by using genetic recombinant techniques, the basis of some of the Company's international patents and patent applications. Furthermore, the processing of conserved internal killer-cell recognition sites allows protection against virtually all the different strains of HIV resulting from mutations.

Limited human testing has demonstrated that Contre Vir™ restored the immune systems of two groups of near death AIDS patients and has rendered them free both of symptoms and of the HIV virus itself. In the first pilot study conducted in 1994 on the basis of a local humanitarian waiver, two AIDS patients with low CD4 counts were administered the Contre Vir™ vaccine. Four additional patients with similar profiles were not granted humanitarian waivers and were not able to receive any treatment. Within six months, the CD4 counts (an inverse measure of severity of AIDS) of the treated patients normalized and symptoms subsided. The two subjects became PCR negative about 2 ½ years after vaccine administration (PCR became available a few years later.) The untreated patients died within a relatively short period of time.As of today, the two treated patients are alive and asymptomatic, with normal CD4 counts and no detectable virus.

A second study, using a randomized, double-blind methodology was conducted in West Africa in 1997, again with a local humanitarian waiver. Sixteen AIDS patients were chosen who had no options for treatment and whose CD4 counts were between 200 and 400. The administration of Contre Vir™ showed, over an 18 week period, a 2-3 log decrease in viral burden in the experimental group and the restoration of normalcy to the CD4 cell count of the treated patients as compared to a control group, which showed no change.



KPIs

21 Issued Patents

Pitch Deck

Traction

  • In early limited trials, shown the efficacy of our HIV therapeutic vaccine to achieve a functional cure.

    November, 1996
  • Welcomed Nobel laureate Prof. Luc Montagnier to our advisory board.

    August, 2011
  • Successfully completed construction of a Biosafety Level 3 (BSL-3) facility, the only private BSL-3 in these parts.

    January, 2012
  • Developed a robust vaccine production process that yields high infectivity rates and good stability of the vaccine. This involved overcoming major roadblocks in the upstream and downstream manufacturing process for the vaccine through our proprietary technology not previously developed.

    November, 2013
  • Successfully completed five GLP animal safety studies; there were no adverse events in any of the studies.

    March, 2016
  • Received conditional approval from South Africa to conduct clinical trials.

    July, 2016
  • Secured initial cooperation of two hospitals in the UK for Phase I clinical trials, pending an on-site quality audit.

    November, 2016
  • Begun work on large-scale production processes for our HIV vaccine using bioreactor technology.

    December, 2015
  • Identified the optimum vector to use as the basis for our therapeutic cancer vaccine technology, and successfully grew and expanded the vector in our laboratory.

    March, 2016
  • Created a library of potential cancer markers to be used as inserts for the vaccine development.

    January, 2016
  • Identified animal models where our cancer vaccine can be tested for proof of concept.

    January, 2016
  • Achieved CE Marking for our saliva-based HIV rapid test kit. The only one ever given to an exclusively saliva based kit.

    May, 2016
Loading...